Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

@article{Remuzzi2004MycophenolateMV,
  title={Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial},
  author={G. Remuzzi and M. Lesti and E. Gotti and M. Ganeva and B. Dimitrov and B. Ene-Iordache and G. Gherardi and D. Donati and M. Salvadori and S. Sandrini and U. Valente and G. Segoloni and G. Mourad and S. Federico and P. Rigotti and V. Sparacino and J. Bosmans and N. Perico and P. Ruggenenti},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={503-512}
}
BACKGROUND Mycophenolate mofetil has replaced azathioprine in immunosuppression regimens worldwide to prevent graft rejection. However, evidence that its antirejection activity is better than that of azathioprine has been provided only by registration trials with an old formulation of ciclosporin and steroid. We aimed to compare the antirejection activity of these two drugs with a new formulation of ciclosporin. METHODS The mycophenolate steroids sparing multicentre, prospective, randomised… Expand
Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
TLDR
In renal transplant recipients who were on immunosuppressive therapy with the cyclosporine microemulsion Neoral, mycophenolate mofetil (MMF) was not better than azathioprine in preventing acute rejection at 21 mo after transplantation and was 15 times more expensive. Expand
A Randomized Trial With Steroids and Antithymocyte Globulins Comparing Cyclosporine/Azathioprine Versus Tacrolimus/Mycophenolate Mofetil (CATM2) in Renal Transplantation
TLDR
Analysis of secondary endpoints showed a lower rate of BPAR, including border line, and a higher eGFR in the Tac/MMF group, which seemed as a better regimen regarding severe secondary outcomes than CsA/Aza allowed a low acute rejection rate. Expand
Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial
TLDR
It is found that in deceased donor kidney transplant recipients on low-dose CsA and no steroids, MMF had no significant benefits over AZA, suggesting thatAZA, due to its lower costs, could safely replace MMF in combination with minimized immunosuppression. Expand
Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review
TLDR
It is shown that MMF used with a calcineurin inhibitor does indeed confer a clinical benefit over AZA by reducing the risk of acute rejection and also possibly reducing graft loss, independent of whether MMF is used in combination with sandimmune, neoral or tacrolimus. Expand
The Effect of Mycophenolate Mofetil and Azathioprine Dose on Renal Allograft Outcome in the United Kingdom
TLDR
This study suggests that less than 1 g of MMF and less than 100 mg of azathioprine are associated with inferior graft outcome, and dose is a useful measure of drug exposure. Expand
Long-term outcome of azathioprine versus mycophenolate mofetil in cyclosporine-based immunosuppression in kidney transplantation: 10 years of experience at a single center.
TLDR
Compared with AZA, MMF offered the clinical benefit of prevention of acute rejection episodes, but displayed similar effects on long-term graft and patient survivals in kidney transplant recipients undergoing cyclosporine-based immunosuppression. Expand
Mycophenolate mofetil in low-risk renal transplantation in patients receiving no cyclosporine: a single-centre experience.
  • O. Raheem, P. Daly, +7 authors D. Hickey
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
There was no difference in acute rejection episodes between MMF and AZA based immunotherapy and there was no significant difference concerning graft survival in the MMF group when compared to AZA group. Expand
Generic formulation of mycophenolate mofetil (Myfenax) in de novo renal transplant recipients: results of 12-month observation.
TLDR
There were no differences in the incidence of acute renal graft rejection, delayed graft function, graft loss, and death in patients with Myfenax vs original CellCept and other formulations of mycophenolate. Expand
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
TLDR
This review of randomised controlled trials (RCTs) aimed to look at the benefits and harms of MPA versus AZA in primary immunosuppressive regimens after kidney transplantation, including their efficacy for maintaining graft and patient survival, prevention of acute rejection, maintaining graft function and their safety, including infections, malignancies and other adverse events. Expand
CONVERSION OF AZATHIOPRINE TO MYCOPHENOLATE MOFETIL AND CHRONIC GRAFT FAILURE PROGRESSION
TLDR
Conversion of AZA to MMF in recipients with CAN was without significant benefit on the progression of chronic graft failure over the period of a year, and morphological changes negatively correlated with graft function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 28 REFERENCES
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
TLDR
MMF is associated with a significantly lower rate of treatment failure compared with AZA during the first 6 months after renal transplantation and produces a clinically important reduction in the incidence, severity, and treatment of acute graft rejection. Expand
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
Mycophenolate mofetil, a new immunosuppressant that selectively inhibits proliferation of T and B lymphocytes, may reduce the frequency and severity of acute graft rejection in adult patients during the first 6 months after renal transplantation. Expand
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients. Expand
PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION
TLDR
MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated. Expand
Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
TLDR
Mycophenolate mofetil appears to be an attractive new agent in the prevention of graft rejection in renal transplant recipients that has shown superior efficacy to azathioprine. Expand
Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single Center
TLDR
The results of these two studies indicate that mycophenolate mofetil could be administered safely to renal allograft recipients for periods up to 2 years, and appears to be effective in reversing acute rejection in a high percentage of patients refractory to other forms of therapy. Expand
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group.
TLDR
For recipients on cyclosporine/mycophenolate mofetil/P with no AR at 90 days, the chance of developing subsequent AR is small; if P is tapered and withdrawn, the risk increases, but the majority remain free of acute and chronic rejection. Expand
COMPLETE REPLACEMENT OF METHYLPREDNISOLONE BY AZATHIOPRINE IN CYCLOSPORINE‐TREATED PRIMARY CADAVERIC RENAL TRANSPLANT RECIPIENTS1 Pressented at the 6th Annual Meeting of the American Society of Transplant Physicians, May 1987, Chicago, IL
TLDR
It is concluded that steroids can be replaced by AZA in the majority of CsA-treated primary cadaveric renal transplant recipients by the end of the first posttransplant year withour an adverse effect on graft survival. Expand
A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporine-treated and azathioprine-treated renal transplant patients.
TLDR
The data indicate that initiating maintenance therapy without PRED is safe but is attended by a greater risk of developing rejection, and that use of this immunosuppressive strategy in renal transplantation is not advised. Expand
The use of mycophenolate mofetil in transplant recipients.
TLDR
The decreased incidence and treatment of acute rejection in patients treated with Mycophenolate mofetil supports its use as a cost-effective option during the first year following transplantation. Expand
...
1
2
3
...